ライフサイエンスコーパス: glycopeptide

1 ring about two key structural changes to the glycopeptide.

2 forms were detected on the Asn144-containing glycopeptide.

3 se search and (7) quantification of O-GalNAc glycopeptides.

4 00 unique phosphopeptides and 1,500 unique N-glycopeptides.

5 ivatized monosaccharides, intact glycans, or glycopeptides.

6 and core fucosylated configurations of the N-glycopeptides.

7 ted, facilitating improved identification of glycopeptides.

8 nt methods for enrichment of N- and O-linked glycopeptides.

9 drous hydrazine to cleave the N-glycans from glycopeptides.

10 yield and identification of N- and O-linked glycopeptides.

11 mmonly used to enrich intact N- and O-linked glycopeptides.

12 major tumor clusters and 5 groups of intact glycopeptides.

13 nd tetra-antennary N-glycans in the forms of glycopeptides.

14 ic peptides, hydrophilic di-/tripeptides and glycopeptides.

15 the analysis of sialyl oligosaccharides and glycopeptides.

16 also improve the characterization of intact glycopeptides.

17 ephalosporins, macrolides and ketolides, and glycopeptides.

18 y facilitates the analysis of acidic and hMW glycopeptides.

19 hromatographic resolution for acidic and hMW glycopeptides.

20 guish between the spectra of N- and O-linked glycopeptides.

21 build a spectral database of N- and O-linked glycopeptides.

22 mmobilized peptides to yield site-containing glycopeptides.

23 piFluor-MS (RFMS) labeled N-glycans and also glycopeptides.

24 to detect potential cross-reactivity amongst glycopeptides.

25 tibiotics with a different target than other glycopeptides.

26 t methods do not afford sequencing of intact glycopeptides.

27 ntification of glycosylation sites or intact glycopeptides.

28 RFMS labeled glycans was similar to that of glycopeptides.

29 ion was 9.5% for cement spacers containing a glycopeptide (27/284) (with or without an aminoglycoside

30 nd de-salting of peptides, (3) enrichment of glycopeptides, (4) solid-phase peptide conjugation and r

31 andem mass spectrometry analysis of O-GalNAc glycopeptides, (6) identification of O-GalNAc glycopepti

32 -terminal of R-lycosin-I, which yielded five glycopeptides (8a-e).

33 Using just five age-associated glycopeptides, a highly accurate age prediction model wa

34 f islets with synthetic AFP analog antiaging glycopeptide (AAGP) would enhance posttransplant engraft

35 , a mimic of the donor substrate, and with a glycopeptide acceptor substrate at 1.80-2.50 angstrom re

36 wer functional status and recent exposure to glycopeptides (adjusted odds ratio [aOR], > 2 for MRSA a

37 oxyl-based hydrogen bonds in self-assembling glycopeptides, affording versatile scaffolds with wide a

38 In particular, isobaric tag labeled glycopeptides after C18 desalting could be readily enric

39 nalysis by integrating glycan sequencing and glycopeptide analysis in a single experiment.

40 tool termed AOGP was developed for intact O-glycopeptide analysis on single proteins.

41 developing computational tools for intact O-glycopeptide analysis, which has greatly hindered the de

42 nt of software solutions enhancing automated glycopeptide analysis.

43 A ligand-receptor interaction between a glycopeptide and a phosphopeptide produces sPGPs that fo

44 the N-glycan type microheterogeneity at the glycopeptide and glycoprotein level.

45 lectively specific glycan linkages on intact glycopeptides and get, to some degree, structure-specifi

46 tegy is being reported for the enrichment of glycopeptides and glycans using a piperazine modified po

47 ysis of biological samples for separation of glycopeptides and glycans.

48 on for the production of biologically active glycopeptides and glycoproteins, including therapeutic m

49 could fucosylate a wide variety of complex N-glycopeptides and intact glycoproteins by using alpha-fu

50 ort O-Pair Search, an approach to identify O-glycopeptides and localize O-glycosites.

51 -MS system for analysis of released glycans, glycopeptides and monosaccharides.

52 e variety of homogeneous, core-fucosylated N-glycopeptides and N-glycoproteins that are hitherto diff

53 sensitive identification of N- and O-linked glycopeptides and open glycan searches.

54 showed near complete specificity for MUC4 TR glycopeptides and peptides, relative to all components o

55 Capturing glycopeptides and phosphopeptides from complicated biolo

56 e method was applied to the determination of glycopeptides and phosphopeptides in clinical specimens,

57 limits as low as 0.1 fmol and 0.05 fmol for glycopeptides and phosphopeptides, respectively), and go

58 for the one-step simultaneous enrichment of glycopeptides and phosphopeptides.

59 mode to determine the branching of isomeric glycopeptides and RFMS labeled glycans.

60 and universal tool through permethylation of glycopeptides and their tandem mass spectrometric analys

61 d for desialylated Abeta1-15 (and Abeta1-17) glycopeptides and to (3) compare the concentrations of t

62 igest of rhPRG4 revealed 135 peptides and 72 glycopeptides, and confirmed that the protease could cle

63 tiple N- and O-glycosylation sites on single glycopeptides, and deriving more glycan structure inform

64 ivity toward an array of selected N-glycans, glycopeptides, and glycoproteins.

65 di-/tripeptides, large hydrophobic peptides, glycopeptides, and hydrophobic drug-linked peptides.

66 ogy for characterizing intact glycoproteins, glycopeptides, and released glycans.

67 d constitutes a new route to access original glycopeptide- and glycolipid-type analogues possessing a

68 class of glycopeptide antibiotics-the known glycopeptide antibiotic complestatin and a newly discove

69 oxide was functionalized with vancomycin, a glycopeptide antibiotic known to have a specific interac

70 to protoplasts that were pretreated with the glycopeptide antibiotic phleomycin, a nonspecific DNA do

71 The glycopeptide antibiotic vancomycin has been widely used

72 ly established dimerization of the important glycopeptide antibiotic vancomycin in four different aqu

73 The glycopeptide antibiotic vancomycin is a mainstay in the

74 Vancomycin, a natural glycopeptide antibiotic, was used as the antibiotic of l

75 Glycopeptide antibiotics (GPAs) are nonribosomal peptide

76 he discovery of vancomycin in the 1950s, the glycopeptide antibiotics (GPAs) have been of great inter

77 The glycopeptide antibiotics (GPAs) serve as an important ex

78 Interest in glycopeptide antibiotics covers many scientific discipli

79 VanA-type resistance to glycopeptide antibiotics in clinical enterococci is regu

80 ycin, and we show that the activity of other glycopeptide antibiotics with this feature can also be s

81 ed total syntheses of vancomycin and related glycopeptide antibiotics, their agylcons, and key analog

82 red two members of a new functional class of glycopeptide antibiotics-the known glycopeptide antibiot

83 synthesis of core-fucosylated, complex CD52 glycopeptide antigen.

84 ccuracy of the modified prediction model for glycopeptides approaches that of the prediction for nonm

85 tides are analysed by LC-MS/MS, while intact glycopeptides are characterised using a dedicated MS met

86 ill undoubtedly facilitate future studies of glycopeptides as clinical biomarkers but should also emb

87 To prove the potential of these glycopeptides as tumor-associated MUC1 antigen mimics, t

88 n of mRNAs, proteins, glycosites, and intact glycopeptides, as well as the expression levels of glyco

89 ke advantage of limited fragmentation of the glycopeptides at low collision energy CID to produce lin

90 mediates H bonds directly or engages the Tn-glycopeptide backbone through water molecules.

91 in interactions involved in tumor spread and glycopeptide-based cancer vaccines.

92 , of the desialylated Abeta1-15 or Abeta1-17 glycopeptides between the AD and non-AD group.

93 Intriguingly, these glycopeptides bind in a bidirectional yet conserved conf

94 in future studies as potential targets in a glycopeptide biomarker panel to further improve accuracy

95 lycopeptides, (6) identification of O-GalNAc glycopeptides by database search and (7) quantification

96 of N-glycans prior to enrichment of O-linked glycopeptides by HILIC improved identification of O-link

97 by HILIC improved identification of O-linked glycopeptides by mass spectrometry.

98 ch in which a readily available bi-antennary glycopeptide can be converted in ten or fewer chemical a

99 The glycan structure of intact glycopeptides can be identified from MS/MS spectra of th

100 gorithm for glycoproteomics in which complex glycopeptides can be identified in complex mixtures to a

101 h three to six O-glycans were detected; nine glycopeptides carried up to three Gd O-glycans.

102 n be relied upon to filter out all related N-glycopeptides carrying additional O-glycans defined by s

103 of an isotopically double-labeled Abeta1-15 glycopeptide, carrying the core 1 Galbeta3GalNAcalpha1-O

104 two sets of tandem mass spectra of N-linked glycopeptides cell lines acquired from breast cancer pat

105 Glycopeptide-centric mass spectrometry has become a popu

106 admissions, greater use of fluoroquinolones, glycopeptides, cephalosporins and other expensive antibi

107 is workflow is suitable for TMT-based intact glycopeptide characterization of glycoproteins.

108 cal proteases (e.g., trypsin) for improved O-glycopeptide characterization with tandem mass spectrome

109 Here, we characterized the first "opine-glycopeptide" class of natural products termed rhabdopla

110 The digestion of O-glycoprotein yields O-glycopeptides cleaved at the N-terminal end of serine an

111 a MUC1-derived positional scanning synthetic glycopeptide combinatorial library (PS-SGCL) that vary i

112 ity and specificity of quantification of the glycopeptides compared to oxonium ion transitions which

113 ided by the structure of the 237 Fab:Tn-OTS8-glycopeptide complex, here we conducted a deep mutationa

114 ed two variant structures, revealed that the glycopeptide contained, in addition to carbohydrate moie

115 This is the first time that a glycopeptide containing aspartic acid and an O-sulfated

116 eutrophil isolation and immunoprecipitation, glycopeptides containing a single site each were generat

117 is extended mass range on various classes of glycopeptides containing phosphorylated, fucosylated, an

118 Twelve variants of glycopeptides corresponding to the HR with three to six

119 A total of 25, 22, and 34 glycopeptides covering all glycosylation sites are enric

120 tes were identified from human serum and 149 glycopeptides derived from 129 glycoproteins with 157 N-

121 Meanwhile, 76 glycopeptides derived from 56 glycoproteins with 83 N-gl

122 GalNAc-glycopeptides derived from mucin MUC1 are an important c

123 its binding characteristics to Tn-containing glycopeptides derived from the MGL ligands mucin 1 (MUC1

124 number of O-glycosites that are present in O-glycopeptides derived from the OpeRATOR digestion of fou

125 Beyond the mucin-type O-glycopeptides discussed here, O-Pair Search also accepts

126 Accordingly, these new glycopeptides display improved binding toward a represen

127 ation methods are necessary to capture the O-glycopeptide diversity present in OpeRATOR digestions.

128 quantification and identification of intact glycopeptides due to inefficient peptide backbone fragme

129 o sequentially isolate phosphopeptides and N-glycopeptides, enabling multiple PTM analyses of the sam

130 otein isolation from biofluid and subsequent glycopeptide enrichment in a single tube.

131 Most importantly, this highly efficient N-glycopeptide enrichment method enables the simultaneous

132 on, protein extraction, and phosphopeptide/N-glycopeptide enrichment to achieve sensitive analyses of

133 tryptic digest of 12 purified glycoproteins, glycopeptide enrichment, deglycosylation with PNGaseF, a

134 hniques, including multienzyme digestion and glycopeptide enrichment, to increase the repertoire of g

135 erum without fractionation of the samples or glycopeptide enrichment.

136 was synthesized by an easy route to improve glycopeptides enrichment efficiency.

137 l enrichment recovery (90.8% and 109.5%) for glycopeptides enrichment, indicating a great potential f

138 o hydrophilic interaction chromatography for glycopeptides enrichment.

139 batch to batch reproducibility (RSD > 1) in glycopeptides enrichment.

140 f mouse tumor cells that bear its cognate Tn-glycopeptide epitope in podoplanin, also called OTS8.

141 that a CD4(+) T cell repertoire recognizes a glycopeptide epitope on gp120 presented by MHCII pathway

142 t high-affinity binding toward Tn-containing glycopeptides, especially at low probing concentrations.

143 y-based method called extraction of O-linked glycopeptides (EXoO) that enables large-scale mapping of

144 rminants to predict divergent members of the glycopeptide family of antibiotics that are likely to po

145 ility and stability even after enrichment of glycopeptides for 20 times.

146 efficient and specific enrichment of intact glycopeptides for identification and quantitation.

147 n, were used separately to generate suitable glycopeptides for online LC tandem MS analysis.

148 ptideGraphMS detected more than 500 unique N-glycopeptides from AXL, triple the number found by a dat

149 tissues, which showed the ability to enrich glycopeptides from complex biological samples.

150 d protein chips showed the ability to enrich glycopeptides from complex mixtures with subsequent MALD

151 Tandem spectra of glycopeptides from fetuin, glycophorin A, ovalbumin and

152 Thirty-four glycopeptides from human serum immunoglobulin G (IgG) tr

153 ubstantially unbiased enrichment of N-linked glycopeptides from human serum.

154 the characterization of glycan structures in glycopeptides from MS/MS analysis.

155 the workflow identified phosphopeptides and glycopeptides from the PTM enrichment.

156 iated carbohydrate antigen (TACA)-containing glycopeptides from the tandem repeat (TR) sequence of MU

157 terizing 1,545 N-glycosites (>5,600 unique N-glycopeptides) from mouse brain tissue.

158 Released glycan and HA-specific glycopeptide glycosylation patterns were examined.

159 l methods for large-scale analyses of intact glycopeptides has limited our abilities both to address

160 nt and mass spectrometric analysis of intact glycopeptides have produced large-scale glycoproteomics

161 provide data sets containing all classes of glycopeptides (high mannose, hybrid, and complex) measur

162 lude that the current software solutions for glycopeptide identification also require further improve

163 tion can significantly improve confidence of glycopeptide identification and structural resolution by

164 nt MS2 quantification, while maintaining the glycopeptide identification capability.

165 accurate, thus providing a solid support for glycopeptide identification in complex samples based on

166 tion confidence levels and generating more O-glycopeptide identifications.

167 ization efficiency and microheterogeneity of glycopeptides identifying glycosylation sites is a chall

168 aracterizing glycans, glycosites, and intact glycopeptides (IGPs) derived from N-linked glycoproteins

169 These studies suggest that glycopeptide immunogens can be designed to stabilize the

170 a new vaccine platform for administration of glycopeptide immunogens for focusing immune responses to

171 Overall, a glycopeptide in the cement spacer was not associated wit

172 glycan and peptide composition of just one N-glycopeptide in the graph was sufficient to identify the

173 cosylation of 12 fucosylated glycoforms of 9 glycopeptides in 7 plasma proteins.

174 fic sialylation patterns of individual Abeta glycopeptides in AD patients and controls.

175 3) compare the concentrations of these Abeta glycopeptides in CSF from 20 AD patients and 20 healthy

176 that will prove useful for analyzing intact glycopeptides in future studies.

177 ure of immunopurified and desialylated Abeta glycopeptides in human CSF and to (2) establish a LC-MS/

178 lly alter the MS(2) fragmentation pattern of glycopeptides in negative mode and the characteristic fe

179 Our data show that over 50% of O-glycopeptides in our sample generated from combined dige

180 h the protein and the polysaccharide creates glycopeptides in the endosome of antigen-presenting cell

181 was sufficient to identify the rest of the N-glycopeptides in the graph.

182 e relative abundances of the most common 159 glycopeptides in the plasma of 97 healthy volunteers.

183 leading to the presence of false glycans or glycopeptides in the sample.

184 N-glycan types of structures linked on each glycopeptide, including high-mannose/hybrid, biantennary

185 Glycopeptide-induced CD4(+) T cell response prior to Env

186 Our identification of gp120 glycopeptide-induced, T cell-specific immune responses o

187 all permeability and is complementary to the glycopeptide inhibition of cell wall synthesis, was foun

188 ides) with 2-fold and 10-fold superior total glycopeptide intensity compared to non-one-pot method (9

189 om immunization with a KLH conjugate of this glycopeptide into rabbits showed high titer antibodies b

190 Additionally, an acceptor glycopeptide is a less efficient substrate for POMGNT2 w

191 For presentation, the peptide portion of the glycopeptide is bound to MHCII, allowing the covalently

192 al infusion concentration of 5 mg.mL(-1) all glycopeptide is dimerized whilst at 19 microg.mL(-1) (a

193 lycoform on the ionization properties of the glycopeptide is observed.

194 This glycopeptide is strongly immunogenic in eliciting glycan

195 laser pulses, efficient photodissociation of glycopeptides is achieved with production of multiple se

196 d on our discovery that the fragmentation of glycopeptides is glycan-structure dependent and glycans

197 ing derivatized polysaccharides, macrocyclic glycopeptides, iso-butylmercaptoquinine, isopropyl macro

198 Herein, we report that the separation of glycopeptide isomers on porous graphitic carbon (PGC)-LC

199 The specific structures of the glycopeptide isomers were identified and confirmed throu

200 ased sequencing and identification of intact glycopeptides largely performed in positive mode.

201 nt identification of these glycoforms at the glycopeptide level by mass spectrometry (MS) requires a

202 se assignment of sialylation linkages at the glycopeptide level is of importance in bottom-up glycopr

203 glycoproteins that can be quantitated to the glycopeptide level makes this method especially suitable

204 ation profile, albeit mainly at a glycan and glycopeptide level of analysis.

205 or antibody fused to chemically synthesized glycopeptide ligands that are agonists of the cation-ind

206 MS and glycopeptide-mapping analyses revealed that HEK-sKlotho

207 Strikingly, in the glycopeptide microarray, the MGL(short) H259T variant lo

208 ed a nonhuman primate (NHP) study using a V3 glycopeptide minimal immunogen that was structurally opt

209 Indeed, O-glycopeptides modified exclusively at the N-terminus wou

210 d complex-type N-glycans in the context of N-glycopeptides, N-glycoproteins, and intact antibodies.

211 The glycopeptide nanostructures amplified signalling of bone

212 We report here on supramolecular sulfated glycopeptide nanostructures, which display a trisulfated

213 a strategy for the permethylation of intact glycopeptides, obtained via controlled protease digest,

214 superior performance in identifying intact O-glycopeptides of the human erythropoietin with a total o

215 lows for the characterization of phospho- or glycopeptides only and enables additional analysis of to

216 Among all synthesized glycopeptides, only 8a exhibited increased cytotoxicity

217 For the glycoforms of a given glycopeptide or set of derivatized glycans, the slope of

218 intensity compared to non-one-pot method (9 glycopeptides) or without enrichment (6 glycopeptides),

219 orm separation for both released glycans and glycopeptides over that reported for chromatography mode

220 ) cell wall is an essential extracytoplasmic glycopeptide polymer that safeguards bacteria against os

221 Peptidoglycan is assembled from a glycopeptide precursor, Lipid II, that is polymerized by

222 ver, PGANT9A and PGANT9B also display unique glycopeptide preferences.

223 he pretreatment of low-abundance glycans and glycopeptides prior to mass spectrometric (MS) analysis.

224 s more than 2,000-fold compared to current O-glycopeptide processing software, while defining O-glyco

225 automated quantitative analysis of the HR O-glycopeptide profiles with sequential deglycosylation to

226 eterogeneity can be captured via large-scale glycopeptide profiling methods enabled by activated ion

227 ative mass spectrometry, mass photometry and glycopeptide profiling revealed significant molecular co

228 f immune suppression, render these unnatural glycopeptides promising candidates for designing alterna

229 pattern was supported by examination of the glycopeptides, providing additional information about th

230 proved SPS/ETD workflow for TMT-based intact glycopeptide quantification and identification.

231 Advancements in sample preparation and glycopeptide quantification are thus needed to better br

232 Detailed analysis of a LLDGSSTEIR glycopeptide released by tryptic digestion, which carrie

233 effectiveness to enrich isobarically labeled glycopeptides remains unclear.

234 nomeric enterococcal VanS kinase involved in glycopeptide resistance regulation.

235 d (9 glycopeptides) or without enrichment (6 glycopeptides), respectively.

236 indings permitted the isomeric separation of glycopeptides resulting from highly specific enzymatic d

237 examine the gas-phase structures of a set of glycopeptides resulting from proteolytic digestion of th

238 These techniques combined with glycopeptide retention time prediction and UHPLC-QqQ con

239 ng additional information to the established glycopeptide-search algorithms and tools.

240 ydrate-aromatic CH-pai bonding that promotes glycopeptide self-assembly.

241 d for the prediction of retention times of N-glycopeptides separated by reversed-phase high performan

242 identified and manually validated by de novo glycopeptide sequencing, of which 514 were sulfated at t

243 re, we present the first study revealing AFP glycopeptide signatures of individual HCC patients, comp

244 urther survival analysis reveals that intact glycopeptide signatures of mesenchymal subtype are assoc

245 The glycopeptide specific CD4(+) T cells display a prominent

246 It allows postacquisition extraction of glycopeptide-specific fragment-ion chromatograms to be a

247 origins of its unique N-terminal long-range glycopeptide specificity, which is the opposite of GalNA

248 e human erythropoietin with a total of 188 O-glycopeptide spectra reported under 1% FDR.

249 ation to score and annotate individual MS/MS glycopeptide spectrum in different fragmentation modes.

250 mics data resulted in annotation of 80% more glycopeptide spectrum matches (glycoPSMs) than previousl

251 mic approach described, using double-labeled glycopeptide standards, will undoubtedly facilitate futu

252 ing four human OGA structures complexed with glycopeptide substrates containing a single O-GlcNAc mod

253 of OGA in complex with each of four distinct glycopeptide substrates that contain a single O-GlcNAc m

254 ated that GalNAc-T12 selects for peptide and glycopeptide substrates through unique interactions with

255 an alter the recognition of both peptide and glycopeptide substrates.

256 A machine-driven platform for glycopeptide synthesis by a reconstructed peptide synthe

257 we have established a dimeric tyrosine-rich glycopeptide system for probing the corresponding hydrog

258 -selective alteration including polyketides, glycopeptides, terpenoids, macrolides, alkaloids, carboh

259 the OpeRATOR digestion of fully sialylated O-glycopeptides that are mass tagged to identify the sialy

260 de enrichment, to increase the repertoire of glycopeptides that can be generated from serum glycoprot

261 S analysis) to identify a number of putative glycopeptides that carried a variety of glycoform substi

262 ed for the glycoforms of individual N-linked glycopeptides, the deglycosylated peptides, and the rele

263 matography (IMAC), followed by enrichment of glycopeptides through mixed anion exchange (MAX) method,

264 For intact glycopeptides, through systematic optimization and evalu

265 2-stage exchange procedure for PJI, adding a glycopeptide to the cement spacer reduces the rate of po

266 dulate the affinity of biologically relevant glycopeptides toward their receptors.

267 study on the implications of complexation on glycopeptide transit in humans, antibiotic bioavailabili

268 s able to distinguish isomeric N-glycans and glycopeptides using both intact IMS and fragment-based I

269 bles rapid setup and analysis of glycans and glycopeptides using mass spectrometry.

270 red the enrichment of intact N- and O-linked glycopeptides using other chromatography methods and fou

271 peptide conjugation and release of O-GalNAc glycopeptides using the OpeRATOR protease, (5) liquid ch

272 ably distinguish between the N- and O-linked glycopeptides using the spectral features of the oxonium

273 its) used for modeling were measured for 602 glycopeptides versus 123 of their deglycosylated analogu

274 ociation spectra, O-Pair Search identifies O-glycopeptides via an ion-indexed open modification searc

275 The glycan structure of a given glycopeptide was determined by collision-induced dissoci

276 ersion of homoserine to aspartic acid in the glycopeptide was successfully accomplished by late stage

277 hod for simultaneous analysis of IgG and IgA glycopeptides was developed and applied on a serum sampl

278 ive and comprehensive enrichment of N-linked glycopeptides was developed to facilitate detection of m

279 The enrichment of O-linked glycopeptides was further improved when a Retain AX cart

280 prehensive structural isomeric separation of glycopeptides was observed by high-resolution MS and con

281 approach for measuring arginine-GlcNAcylated glycopeptides, we assessed the global profile of arginin

282 tructures and Tyr-10 attachment sites of the glycopeptides, we did not observe any quantitative diffe

283 These glycopeptides were attributable to 11 different peptide

284 13 glycopeptides were found to be associated with gender an

285 d of database for data mining, 1380 unique N-glycopeptides were identified and manually validated by

286 ll samples together, 143 individual N- and O-glycopeptides were reliably quantified.

287 In total, the abundances of over 600 glycopeptides were simultaneously monitored, some of whi

288 facilitating the analysis of these charged O-glycopeptides, which are often important in biological p

289 re used for the identification of the intact glycopeptides, while the quantitative comparison of site

290 proteoglycan core proteins by identifying CS-glycopeptides with a combination of biochemical enrichme

291 O-glycopeptides with a modified N-terminal residue, such a

292 The ionization properties of the glycopeptides with different classes of glycan structura

293 harides at Tyr(4) and Tyr(4') shows that the glycopeptides with either alpha- or beta-anomers exhibit

294 ine the genomes of Actinomycetes species for glycopeptides with novel targets.

295 Using synthetic glycopeptides with O-GalNAc (the Tn antigen) or O-GlcNAc

296 emonstrated that the method is selective for glycopeptides with O-GalNAc and can distinguish between

297 d retention time differences were actually N-glycopeptides with the same peptide backbone but differe

298 y the MS(3) spectra of the oligomannosylated glycopeptides with the same Y1 ion.

299 thod and confidence in the identification of glycopeptides with the Tn antigen by mass spectrometry.

300 assay has high purification specificity (20 glycopeptides) with 2-fold and 10-fold superior total gl